Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements [Yahoo! Finance]
Alto Neuroscience, Inc. (ANRO)
Company Research
Source: Yahoo! Finance
— Alto has developed a modified-release, once-daily oral formulation of ALTO-101; the Company plans to explore partnering opportunities for this formulation — — Development of ALTO-207 remains the top priority for the Company; Phase 2b on track to initiate in 1H 2026 — MOUNTAIN VIEW, Calif., April 01, 2026 BUSINESS WIRE )--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced topline data from its Phase 2 proof-of-concept (POC) clinical trial evaluating ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS), and provided an update on the Company's pipeline and prioritization. ALTO-101 did not achieve statistical significance on primary electroencephalography (EEG) or cognitive endpoints versus placebo; however, the study demonstrated directional improvements across certain EEG measures, including a near-significant effect on theta-ITC (n=83,
Show less
Read more
Impact Snapshot
Event Time:
ANRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANRO alerts
High impacting Alto Neuroscience, Inc. news events
Weekly update
A roundup of the hottest topics
ANRO
News
- Alto Neuroscience (ANRO) had its price target lowered by Robert W. Baird from $41.00 to $38.00. They now have an "outperform" rating on the stock.MarketBeat
- Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.MarketBeat
- Alto Neuroscience (ANRO) had its price target lowered by JonesTrading from $49.00 to $44.00. They now have a "buy" rating on the stock.MarketBeat
- Alto Neuroscience (ANRO) had its price target lowered by Wedbush from $22.00 to $21.00. They now have a "neutral" rating on the stock.MarketBeat
- Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $30.00 price target on the stock.MarketBeat
ANRO
Earnings
- 3/16/26 - Miss
ANRO
Sec Filings
- 4/10/26 - Form S-3
- 4/1/26 - Form 8-K
- 3/26/26 - Form ARS
- ANRO's page on the SEC website